Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Accumulated Expenses (2016 - 2026)

Gyre Therapeutics has reported Accumulated Expenses over the past 16 years, most recently at $14.3 million for Q4 2025.

  • Quarterly Accumulated Expenses rose 35.14% to $14.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.3 million through Dec 2025, up 35.14% year-over-year, with the annual reading at $14.3 million for FY2025, 35.14% up from the prior year.
  • Accumulated Expenses was $14.3 million for Q4 2025 at Gyre Therapeutics, up from $11.8 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $17.2 million in Q1 2025 and troughed at $180000.0 in Q4 2021.
  • The 5-year median for Accumulated Expenses is $5.9 million (2021), against an average of $6.7 million.
  • Year-over-year, Accumulated Expenses tumbled 92.73% in 2021 and then skyrocketed 5046.67% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $180000.0 in 2021, then skyrocketed by 5046.67% to $9.3 million in 2022, then rose by 28.83% to $11.9 million in 2023, then dropped by 11.06% to $10.6 million in 2024, then surged by 35.14% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Accumulated Expenses are $14.3 million (Q4 2025), $11.8 million (Q3 2025), and $14.9 million (Q2 2025).